Last reviewed · How we verify
HAI conventional chemotherapy
At a glance
| Generic name | HAI conventional chemotherapy |
|---|---|
| Also known as | Campto, Eloxatin |
| Sponsor | Association pour la Recherche sur le Temps Biologique et la Chronothérapie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT (PHASE2)
- HAIC Compared With TACE in Huge Hepatocellular Carcinoma
- Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (PHASE1)
- Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (PHASE2)
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma (PHASE1)
- Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (PHASE2)
- Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (PHASE2)
- Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: